Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?

Trends Cardiovasc Med. 2020 Nov;30(8):463-469. doi: 10.1016/j.tcm.2019.10.001. Epub 2019 Oct 11.

Abstract

Inflammation has a strong role in the development of atherosclerotic cardiovascular disease (ASCVD). Several systemic inflammatory conditions have been linked to an increased risk of ASCVD; however, this has not been well established in Inflammatory Bowel Disease (IBD). IBD is comprised of Ulcerative Colitis and Crohn's disease, both of which involve chronic inflammation of the intestinal tract, often with evidence of systemic involvement. Several ASCVD risk factors such as smoking, diabetes, poor diet and the presence of obesity may increase the risk of ASCVD in patients suffering from IBD, despite a lower prevalence of hypertension and hypercholesterolemia. Medications used to treat IBD and target inflammation, such as steroids, may also accelerate the risk of the risk for ASCVD heart failure while exacerbating ASCVD risk factors. Several studies have demonstrated an elevated risk of acute myocardial infarction and stroke in these patients, most notably in women and in younger patients. Some cohort studies have also suggested a link between IBD and both atrial fibrillation and heart failure, particularly during periods of active flares. All IBD patients, particularly younger individuals, should be screened for ASCVD risk factors with aggressive risk factor modification to reduce the risk of cardiovascular events. Further research is needed to identify how to prevent and treat cardiovascular events that occur in patients with IBD, particularly during active flares.

Keywords: ASCVD risk assessment; Atrial fibrillation; Cardiovascular disease; Heart failure; Inflammation; Inflammatory bowel disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / adverse effects
  • Atherosclerosis / epidemiology*
  • Atherosclerosis / immunology
  • Atherosclerosis / metabolism
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / epidemiology*
  • Colitis, Ulcerative / immunology
  • Colitis, Ulcerative / metabolism
  • Comorbidity
  • Crohn Disease / drug therapy
  • Crohn Disease / epidemiology*
  • Crohn Disease / immunology
  • Crohn Disease / metabolism
  • Gastrointestinal Agents / adverse effects
  • Heart Disease Risk Factors
  • Humans
  • Inflammation Mediators / metabolism
  • Life Style
  • Prognosis
  • Risk Assessment
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Inflammation Mediators